PIII vs RCUS: Which Stock Is the Better Buy?
P3 Health Partners Inc. and Arcus Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — PIII vs RCUS, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| P3 Health Partners Inc. (PIII) | Arcus Biosciences, Inc. (RCUS) | |
|---|---|---|
| Market cap | $2.7B | $2.8B |
| Revenue (latest FY) | $1.46B | $247.00M |
| Net income (latest FY) | $-147.95M | $-353.00M |
| Revenue growth (5y CAGR) | 58.6% | 25.9% |
| Net margin | -10.1% | -142.9% |
| Return on equity | 95.3% | -55.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | — | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full PIII vs RCUS breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open PIII's full financials → Open RCUS's full financials →More comparisons
Frequently asked questions
Which is bigger, PIII or RCUS?
Arcus Biosciences, Inc. is larger by market capitalization — $2.8B versus $2.7B.
Which grows faster, PIII or RCUS?
Over the last five fiscal years, P3 Health Partners Inc. grew revenue faster — 58.6%/yr versus 25.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.